SB 902 - This act provides that an enrollee's health benefit plan shall not deny coverage of a nonopioid prescription drug in favor of an opioid drug, require the enrollee to try an opioid drug before covering the nonopioid prescription drug, or require a higher level of cost-sharing for a nonopioid prescription drug than for an opioid drug. This act shall apply to health benefit plans delivered, issued for delivery, continued, or renewed in this state on or after January 1, 2027. This act is identical to HB 1680 (2026), HB 1966 (2026), and similar to SCS/SB 841 (2026), the truly agreed to and finally passed HCS/SB 1019 (2026), SB 1449 (2026), SB 158 (2025), the truly agreed to and finally passed HCS/HB 2372 (2026), HCS/HBs 2642, 2296, 1966 & 1680 (2026), SB 158 (2025), HB 804 (2025), and provisions in HCS/SS/SB 7 (2025). TAYLOR MIDDLETON

2026 Regular Session

Health plans may not deny, delay, or charge more for nonopioid prescriptions for acute pain when prescribed by a licensed clinician.

Voted Do Pass S Insurance and Banking Committee

Purpose and intent

SB 902 aims to ensure that health benefit plans in Missouri do not penalize the use of nonopioid medications for acute pain when prescribed by a licensed health care professional. Specifically, it prohibits plans from denying coverage, requiring patients to try an opioid first, or imposing higher cost-sharing for nonopioid drugs when a nonopioid option is prescribed for acute pain.

Key provisions and changes

Defines terms for the section, including:

Acute pain: pain resulting from disease, trauma, or other causes expected to last 30 days or fewer.
Enrollee, health benefit plan, health care professional: aligned with existing definitions in chapter 376.

Prohibitions for health benefit plans when a licensed health care professional prescribes a nonopioid for acute pain: 1) Prohibits denial of coverage for the nonopioid prescription in favor of an opioid. 2) Prohibits requiring the enrollee to try an opioid before the nonopioid is covered. 3) Prohibits charging a higher cost-sharing for the nonopioid than for the opioid.

Effective date: The act applies to health benefit plans delivered, issued for delivery, continued, or renewed on or after January 1, 2027.

Relationship to other legislation: SB 902 is identical or substantially similar to several other Missouri bills from 2025–2026 (including HB/SB counterparts and various versioned companions), indicating a broader policy movement on analgesic coverage.

Who would be affected

Enrollees under Missouri health benefit plans: particularly those with acute pain conditions who are prescribed nonopioid medications.

Health care professionals: who prescribe nonopioid treatments for acute pain, as their prescriptions would trigger protections against plan limitations.

Health insurers and plan sponsors: must align coverage practices with the new prohibition and adjust prior authorization and cost-sharing rules accordingly.

Employers and purchasers of plans: indirectly affected via changes to plan design and coverage requirements.

Procedural and timeline notes

Effective for plans on or after January 1, 2027.

Status: As of the latest action, SB 902 has moved through committee and is positioned for potential floor action, reflecting ongoing legislative activity in 2026.

Related legislation: Part of a broader policy package with multiple identical or similar bills across the 2025–2026 sessions, suggesting convergence on nonopioid coverage protections.

Practical impact and considerations

Access and affordability: aims to improve access to nonopioid analgesics, potentially reducing opioid exposure by ensuring nonopioids are covered fairly.

Administrative implications: insurers may need to adjust formulary decisions, prior authorization processes, and cost-sharing tiers to remove disincentives for nonopioids.

Public health rationale: aligns with efforts to reduce opioid-related risks while ensuring appropriate pain management options remain available.

If you’d like, I can compare SB 902 to its identified companion bills to highlight any nuanced differences or provide a simple summary table.